In the Claims

The listing of claims will replace all prior versions and listings of claims in the application.

Listings of claims

1. (original) A compound of formula (I) or a pharmaceutically acceptable salt or *in vivo*-hydrolysable precursors thereof:



(I)

wherein:

R^1 and R^2 are at each occurrence independently selected from H, optionally substituted C_{1-6}alkyl, or optionally substituted heterocyclyl; with the proviso that R^1 and R^2 are not both H;

or R^1 and R^2 and the N to which they are attached in combination form an optionally substituted heterocyclyl;

R^4 is selected from H, OH, optionally substituted carbocyclyl, optionally substituted heterocyclyl, or optionally substituted C_{1-6}alkyl;

R^5 is selected from H, optionally substituted carbocyclyl, or optionally substituted C_{1-6}alkyl.

2. (original) A compound of formula (I) or a pharmaceutically salt or an *in vivo*-hydrolysable precursor thereof as recited in claim 1 wherein R^2, R^4, and R^5 have any of the meanings defined in claim 1 and

R^1 is an optionally substituted heterocyclyl.

3. (original) A compound of formula (I) or a pharmaceutically salt or an *in vivo*-hydrolysable precursor thereof as recited in claim 1 wherein R^2, R^4, and R^5 have any of the meanings defined in claim 1 and R^1 is an optionally substituted heterocyclyl wherein 1,2, or 3 substitutents is/are independently selected from halogen, nitro, amino, cyano, trifluoromethyl,

alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, hydroxy, alkylhydroxy, carbonyl, -CH(OH)CH_3, -CH_2NH-alkyl-OH, alkyl-(OH)CH_3, -CH_2-phenyl-$(OCH_3)_2$, -Oalkyl, -OCH_3, -Ophenyl, -OCOalkyl, -NHCHO, -Nalkyl, -N-(alkyl)-CHO, -NH-CO-amino, -N-(alkyl)-CO-amino, -NH-COalkyl, -N-(alkyl)-COalkyl, -carboxy, -amidino, -CO-amino, -CO-alkyl, -CO_2alkyl, mercapto, -Salkyl, -SCH_2furanyl, -SO(alkyl), -SO_2(alkyl), -SO_2-amino, -alkylsulfonylamino, phenyl, anisole, dimethoxyphenyl, trimethoxyphenyl, halophenyl, cycloalkyl, heterocyclyl, -alkyl-NH-cycloalkyl, -alkyl-NH- heterocyclyl, -alkyl-NH-alkyl-OH, -C(=O)$OC(CH_3)_3$, -$N(CH_3)_2$, -$N(CH_2CH_3)_2$, -alkyl-NH-alkyl- heterocyclyl, -alkyl-aryl, -methyl-phenyl, alkyl-polycyclyl, alkyl-amino, alkyl-hydroxy, -CH_2NH-alkyl-heterocyclyl, -CH_2NHCH2$CH(CH_3)_2$, vicinal -O(alkyl)O-, vicinal -OC(haloalkyl)O-, vicinal -CH_2O(alkyl)O-, vicinal -S(alkyl)S- and –O(alkyl)S-.

4. (currently amended) A compound of formula (I) or a pharmaceutically salt or an *in vivo*-hydrolysable precursor thereof as recited in claim 1 wherein R^2, R^4, and R^5 have any of the meanings defined in claim 1 and R^1 is an optionally substituted heterocyclyl wherein 1,2, or 3 ~~substitutents~~ substituents is/are independently selected from: -OH, C(=O)$OC(CH_3)_3$, NH_2, $C_{1\text{-}6}$alkyl, methoxybenzene, or dimethoxy benezene.

5. (original) A compound of formula (I) or a pharmaceutically salt or an *in vivo*-hydrolysable precursor thereof as recited in claim 1 wherein R^2, R^4, and R^5 have any of the meanings defined in claim 1 and

R^1 is a heterocyclyl wherein heterocyclyl is selected from piperdinyl, pyridinyl, pyrrolidinyl, pyrazinyl, azepanyl, azetidinyl, azabicyclozinyl, furanyl, thienyl.

6. (original) A compound of formula (I) or a pharmaceutically salt or an *in vivo*-hydrolysable precursor thereof as recited in claim 1 wherein R^1, R^4, and R^5 have any of the meanings defined in claim 1 and

R^2 is H.

7. (original) A compound of formula (I) or a pharmaceutically salt or an *in vivo*-hydrolysable precursor thereof as recited in claim 1 wherein R^1, R^2, and R^5 have any of the meanings defined in claim 1 and

R^4 is H.

8. (original) A compound of formula (I) or a pharmaceutically salt or an *in vivo*-hydrolysable precursor thereof as recited in claim 1 wherein R^1, R^2, and R^4 have any of the meanings defined in claim 1 and

R^5 is H or an optionally substituted C_{1-6}alkyl.

9. (currently amended) A compound of formula (I) or a pharmaceutically salt or an *in vivo*-hydrolysable precursor thereof as recited in claim 1 wherein R^1, R^2, and R^4 have any of the meanings defined in claim 1 and

R^5 is H or an optionally substituted C_{1-6}alkyl wherein 1,2 or 3 ~~substitutents~~ substituents is/are independently selected from: NH_2, $NHCH_3$, $N(CH_2CH_3)_2$, $N(CH_3)_2$, OCH3, OH, -C_{1-6}alkyl, morpholino, piperidinyl, pyrrolodinyl.

10. (original) A compound of formula (I) or a pharmaceutically salt or an *in vivo*-hydrolysable precursor thereof as recited in claim 1 wherein R^1, R^2, and R^4 have any of the meanings defined in claim 1 and

R^5 is H or an optionally substituted C_{1-3}alkyl.

11. (currently amended) A compound of formula (I) or a pharmaceutically salt or an *in vivo*-hydrolysable precursor thereof as recited in claim 1 wherein R^1, R^2, and R^4 have any of the meanings defined in claim 1 and

R^5 is H or an optionally substituted C_{1-3}alkyl wherein 1,2 or 3 ~~substitutents~~ substituents is/are independently selected from: NH_2, $NHCH_3$, $N(CH_2CH_3)_2$, $N(CH_3)_2$, OCH3, OH, -C_{1-6}alkyl, morpholino, piperidinyl, pyrrolodinyl.

12. (original) A compound of formula (I) or a pharmaceutically salt or an *in vivo*-hydrolysable precursor thereof, as recited in claim 1 wherein:

R^1 is an optionally substituted heterocyclyl;

R^2 is H;

R^4 is H;

R^5 is H or an optionally substituted C_{1-6}alkyl.

13. (currently amended) A compound of formula (I) or a pharmaceutically salt or an *in vivo*-hydrolysable precursor thereof, as recited in claim 1 wherein:

R^1 is an optionally substituted heterocyclyl wherein the ~~substitutent~~ substituent is selected from one or more of the following: $-NH_2$, C_{1-6}alkyl, $-C(=O)OC(CH_3)_3$,

R^2 is H;

R^4 is H;

R^5 is H or an optionally substituted C_{1-6}alkyl wherein the ~~substitutent~~ substituent is selected from one or more of the following: $-C_{1-6}$alkyl, $-N(C_{1-3}alkyl)_2$.

14. (currently amended) A compound of formula (I) or a pharmaceutically salt or an *in vivo*-hydrolysable precursor thereof, as recited in claim 1 wherein:

R^1 is an optionally substituted heterocyclyl wherein the ~~substitutent~~ substituent is selected from one or more of the following: $-NH_2$, C_{1-6}alkyl, $-C(=O)OC(CH_3)_3$,

R^2 is H;

R^4 is H;

R^5 is H or an optionally substituted C_{1-3}alkyl wherein 1,2 or 3 ~~substitutent~~ substituent is/are independently selected from: NH_2, $NHCH_3$, $N(CH_2CH_3)_2$, $N(CH_3)_2$, OCH3, OH, $-C_{1-6}$alkyl, morpholino, piperidinyl, pyrrolodinyl.

15. A compound of formula (I) or a pharmaceutically salt or an *in vivo*-hydrolysable precursor thereof, as recited in claim 1 wherein:

R^1 is a heterocyclyl;

R^2 is H;

R^4 is H;

R^5 is H or a C_{1-6}alkyl.

16. (original) A compound of formula (I) or a pharmaceutically salt or an *in vivo*-hydrolysable precursor thereof, as recited in claim 1 wherein:

R^1 is a 6-membered heterocyclyl containing at least one N in the ring;

R^2 is H;

R^4 is H;

R^5 is a C_{1-3}alkyl.

17. (original) A compound of formula (I) selected from:
tert-butyl 3-{[(2-[(aminocarbonyl)amino]-5-{4-[2-(diethylamino)ethoxy]phenyl}-3-thienyl)carbonyl]amino}piperidine-1-carboxylate;
2-[(aminocarbonyl)amino]-5-{4-[2-(diethylamino)ethoxy]phenyl}-N-piperidin-3-ylthiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-{3-[2-(diethylamino)ethoxy]phenyl}-N-piperidin-3-ylthiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[(3S)-piperidin-3-yl]thiophene-3-carboxamide;
tert-butyl 3-{[(2-[(aminocarbonyl)amino]-5-{3-[2-(diethylamino)ethoxy]phenyl}-3-thienyl)carbonyl]amino}piperidine-1-carboxylate;
2-[(aminocarbonyl)amino]-5-{4-[2-(diethylamino)ethoxy]phenyl}-N-piperidin-4-ylthiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-N-[(3R)-azepan-3-yl]-5-(4-methoxyphenyl)thiophene-3-carboxamide;
N-(3-[(4-aminopiperidin-1-yl)carbonyl]-5-{4-[2-(diethylamino)ethoxy]phenyl}-2-thienyl)urea;
2-[(aminocarbonyl)amino]-5-{4-[2-(diethylamino)ethoxy]phenyl}-N-[3-(hydroxymethyl)phenyl]thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-{3-[2-(diethylamino)ethoxy]phenyl}-N-piperidin-4-ylthiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-N-(2-aminoethyl)-5-(4-methoxyphenyl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-piperidin-4-ylthiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-{3-[2-(diethylamino)ethoxy]phenyl}-N-pyridin-3-ylthiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(1-methylpiperidin-4-yl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[(3S)-1-methylazepan-3-yl]thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-{3-[2-(diethylamino)ethoxy]phenyl}-N-[3-(hydroxymethyl)phenyl]thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-{4-[2-(diethylamino)ethoxy]phenyl}-N-pyrrolidin-3-ylthiophene-3-carboxamide;

2-[(aminocarbonyl)amino]-5-{4-[2-(diethylamino)ethoxy]phenyl}-N-pyridin-3-ylthiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[(3S)-1-methylpiperidin-3-yl]thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-{3-[2-(diethylamino)ethoxy]phenyl}-N-pyrrolidin-3-ylthiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[(3R)-piperidin-3-ylmethyl]thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[(3S)-pyrrolidin-3-yl]thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[(3R)-pyrrolidin-3-yl]thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-N-[2-(dimethylamino)ethyl]-5-(4-methoxyphenyl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-N-[2-(diethylamino)ethyl]-5-(4-methoxyphenyl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-N-[(3S)-azepan-3-yl]-5-(4-methoxyphenyl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[(3R)-piperidin-3-yl]thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(piperidin-4-ylmethyl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-pyrrolidin-3-ylthiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-N-(1-ethylpiperidin-3-yl)-5-(4-methoxyphenyl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-N-[(3S)-1-ethylazepan-3-yl]-5-(4-methoxyphenyl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(3-hydroxyphenyl)-N-piperidin-4-ylthiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)-N-piperidin-4-ylthiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)-N-piperidin-4-ylthiophene-3-carboxamide;
tert-butyl (3S)-3-({[2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-3-thienyl]carbonyl}amino)pyrrolidine-1-carboxylate;
2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-piperidin-3-ylthiophene-3-carboxamide;

2-[(aminocarbonyl)amino]-N-(1-benzylpiperidin-4-yl)-5-(4-methoxyphenyl)thiophene-3-carboxamide;
tert-butyl 3-({[2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-3-thienyl]carbonyl}amino)piperidine-1-carboxylate;
2-[(aminocarbonyl)amino]-5-[4-(2-piperidin-1-ylethoxy)phenyl]-N-(2-pyridin-4-ylethyl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-[4-(2-piperidin-1-ylethoxy)phenyl]-N-(2-pyridin-4-ylethyl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-N-azetidin-3-yl-5-(4-methoxyphenyl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[(2S)-pyrrolidin-2-ylmethyl]thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-pyridin-4-ylthiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(2-piperazin-1-ylethyl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(2-piperidin-1-ylethyl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-N-1-azabicyclo[2.2.2]oct-3-yl-5-(4-methoxyphenyl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-N-(2-hydroxyethyl)-5-(4-hydroxyphenyl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-N-(trans-4-hydroxycyclohexyl)-5-(4-methoxyphenyl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)-N-(2-pyridin-4-ylethyl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(2-piperazin-1-ylethyl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(2-pyridin-4-ylethyl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)-N-(2-pyridin-3-ylethyl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(2-pyridin-3-ylethyl)thiophene-3-carboxamide;

2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(2-methoxyphenyl)-N-piperidin-4-ylthiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(tetrahydrofuran-2-ylmethyl)thiophene-3-carboxamide;
tert-butyl (3R)-3-({[2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-3-thienyl]carbonyl}amino)piperidine-1-carboxylate;
2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(pyridin-3-ylmethyl)thiophene-3-carboxamide;
tert-butyl 3-({[2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-3-thienyl]carbonyl}amino)azetidine-1-carboxylate;
2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(pyridin-4-ylmethyl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(3-methoxypropyl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[2-(2-thienyl)ethyl]thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(2-thienylmethyl)thiophene-3-carboxamide;
N-[3-(1,4-diazepan-1-ylcarbonyl)-5-(4-methoxyphenyl)-2-thienyl]urea;
2-[(aminocarbonyl)amino]-N-(2-methoxyethyl)-5-(4-methoxyphenyl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)-N-(2-thienylmethyl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-N-{2-[(2-furylmethyl)thio]ethyl}-5-(4-methoxyphenyl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)-N-[2-(2-thienyl)ethyl]thiophene-3-carboxamide;
N-(3-[(4-aminopiperidin-1-yl)carbonyl]-5-{3-[2-(diethylamino)ethoxy]phenyl}-2-thienyl)urea;
2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[(3R)-piperidin-3-ylmethyl]thiophene-3-carboxamide;

2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(1,2,3,4-tetrahydroquinolin-3-yl)thiophene-3-carboxamide;

2-[(aminocarbonyl)amino]-N-(1,3-benzodioxol-5-ylmethyl)-5-(4-methoxyphenyl)thiophene-3-carboxamide;

2-[(aminocarbonyl)amino]-N-(3-methoxybenzyl)-5-(4-methoxyphenyl)thiophene-3-carboxamide;

2-[(aminocarbonyl)amino]-N-[2-(3,4-dimethoxyphenyl)ethyl]-5-(4-methoxyphenyl)thiophene-3-carboxamide;

2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[(5-methyl-2-furyl)methyl]thiophene-3-carboxamide;

2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(pyridin-2-ylmethyl)thiophene-3-carboxamide;

2-[(aminocarbonyl)amino]-N-(4-fluorobenzyl)-5-(4-methoxyphenyl)thiophene-3-carboxamide;

tert-butyl 4-({[2-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)-3-thienyl]carbonyl}amino)piperidine-1-carboxylate;

2-[(aminocarbonyl)amino]-N-(2-methoxybenzyl)-5-(4-methoxyphenyl)thiophene-3-carboxamide;

2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(2-phenoxyethyl)thiophene-3-carboxamide;

2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(2-pyridin-2-ylethyl)thiophene-3-carboxamide;

tert-butyl 4-({[2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-3-thienyl]carbonyl}amino)piperidine-1-carboxylate;

2-[(aminocarbonyl)amino]-N-(4-methoxybenzyl)-5-(4-methoxyphenyl)thiophene-3-carboxamide;

2-[(aminocarbonyl)amino]-5-{4-[2-(diethylamino)ethoxy]phenyl}-N-[(3S)-piperidin-3-yl]thiophene-3-carboxamide;

2-[(aminocarbonyl)amino]-5-{4-[2-(diethylamino)ethoxy]phenyl}-N-[(3R)-piperidin-3-yl]thiophene-3-carboxamide;

tert-butyl (3S)-3-{[(2-[(aminocarbonyl)amino]-5-{4-[2-(diethylamino)ethoxy]phenyl}-3-thienyl)carbonyl]amino}piperidine-1-carboxylate;

2-[(aminocarbonyl)amino]-N-[(3S)-azepan-3-yl]-5-{4-[2-(diethylamino)ethoxy]phenyl}thiophene-3-carboxamide;

tert-butyl (3R)-3-{[(2-[(aminocarbonyl)amino]-5-{4-[2-(diethylamino)ethoxy]phenyl}-3-thienyl)carbonyl]amino}piperidine-1-carboxylate;

N-[3-{[(3S)-3-aminoazepan-1-yl]carbonyl}-5-(4-methoxyphenyl)-2-thienyl]urea;

5-{4-[2-(diethylamino)ethoxy]phenyl}-2-{[(pyrazin-2-ylamino)carbonyl]amino}-N-[(3S)-pyrrolidin-3-yl]thiophene-3-carboxamide;

5-{3-[2-(diethylamino)ethoxy]phenyl}-2-{[(pyrazin-2-ylamino)carbonyl]amino}-N-[(3S)-pyrrolidin-3-yl]thiophene-3-carboxamide;

5-{3-[2-(diethylamino)ethoxy]phenyl}-N-piperidin-4-yl-2-{[(pyrazin-2-ylamino)carbonyl]amino}thiophene-3-carboxamide;

N-[(3S)-azepan-3-yl]-5-(4-methoxyphenyl)-2-{[(pyrazin-2-ylamino)carbonyl]amino}thiophene-3-carboxamide;

5-{3-[2-(diethylamino)ethoxy]phenyl}-N-piperidin-3-yl-2-{[(pyrazin-2-ylamino)carbonyl]amino}thiophene-3-carboxamide;

N-(2-aminoethyl)-5-(4-methoxyphenyl)-2-{[(pyrazin-2-ylamino)carbonyl]amino}thiophene-3-carboxamide;

5-{4-[2-(diethylamino)ethoxy]phenyl}-N-piperidin-3-yl-2-{[(pyrazin-2-ylamino)carbonyl]amino}thiophene-3-carboxamide;

5-(4-methoxyphenyl)-N-piperidin-4-yl-2-{[(pyrazin-2-ylamino)carbonyl]amino}thiophene-3-carboxamide;

tert-butyl 3-{[(5-{3-[2-(diethylamino)ethoxy]phenyl}-2-{[(pyrazin-2-ylamino)carbonyl]amino}-3-thienyl)carbonyl]amino}piperidine-1-carboxylate;

5-{4-[2-(diethylamino)ethoxy]phenyl}-N-piperidin-4-yl-2-{[(pyrazin-2-ylamino)carbonyl]amino}thiophene-3-carboxamide;

5-(4-methoxyphenyl)-2-{[(pyrazin-2-ylamino)carbonyl]amino}-N-[(3S)-pyrrolidin-3-yl]thiophene-3-carboxamide;

N-[3-(1,4-diazepan-1-ylcarbonyl)-5-(4-methoxyphenyl)-2-thienyl]-N'-pyrazin-2-ylurea;

N-[3-[(3-aminopyrrolidin-1-yl)carbonyl]-5-(4-methoxyphenyl)-2-thienyl]-N'-pyrazin-2-ylurea;

tert-butyl 4-{[(5-(4-methoxyphenyl)-2-{[(pyrazin-2-ylamino)carbonyl]amino}-3-thienyl)carbonyl]amino}piperidine-1-carboxylate;

tert-butyl 3-{[(5-{4-[2-(diethylamino)ethoxy]phenyl}-2-{[(pyrazin-2-ylamino)carbonyl]amino}-3-thienyl)carbonyl]amino}piperidine-1-carboxylate;
5-[4-(2-diethylamino-ethoxy)-phenyl]-2-(3-hydroxy-urea)-thiophene-3-carboxylic acid-(S)-piperidin-3-ylamide;
2-[(aminocarbonyl)amino]-N-[(3S)-azepan-3-yl]-5-(3-methoxyphenyl)thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(2-hydroxyphenyl)-*N*-[(3*S*)-piperidin-3-yl]thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)-N-[(*3S*)-piperidin-3-yl]thiophene-3-carboxamide;
2-[(aminocarbonyl)amino]-5-[2-(benzyloxy)phenyl]-*N*-[(*3S)*-piperidin-3-yl]thiophene-3-carboxamide.

18. (canceled)

19. (canceled)

20. (currently amended) A method for the treatment of cancer comprising administering to a human a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in ~~any one of claims 1 to 17~~ claim 1.

21. (currently amended) A method for the treatment of breast cancer, colorectal cancer, ovarian cancer, lung (non small cell) cancer, malignant brain tumors, sarcomas, melanoma and lymphoma by ~~administring~~ administering a compound of formula I or a pharmaceutically acceptable salt thereof as defined in ~~any one of claims 1 to 17~~ claim 1.

22. (currently amended) A method of treating cancer by administering to a human a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in ~~any one of claims 1 to 17~~ claim 1 and an anti-tumor agent.

23. (currently amended) A method of treating cancer by administering to a human a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in ~~any one of claims 1 to 17~~ claim 1 and a DNA damaging agent.

24. (currently amended) A method for the treatment of infections associated with cancer comprising administering to a host in need of such treatment a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in ~~any one of claims 1 to 17~~ claim 1.

25. (currently amended) A method for the prophylaxis treatment of infections associated with cancer comprising administering to a host in need of such treatment a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in ~~any one of claims 1 to 17~~ claim 1.

26. (currently amended) A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in ~~any one of claims 1 to 17~~ claim 1 together with at least one pharmaceutically acceptable carrier, diluent or ~~excipient~~ excipient.

27. (currently amended) A process for the preparation of a compound of formula (I) or a ~~phrmaceutically~~ pharmaceutically acceptable salt or *in vivo*-hydrolysable precursors thereof as defined in ~~any one of claims 1 to 17~~ claim 1, which comprises:

(a) the reaction of a 2-aminothiophene shown below as Formula II



II

wherein the hydrogen at the 2-amino position is displaced to form an amide, shown as formula III below



III

wherein the methyl ester is converted to an amide utilizing the desired amine in ~~conjuntion~~ conjunction with an aluminate organometallic complex, to give the product shown as formula IV below:



IV

Wherein the amide is converted to various substituted secondary ureas by the reaction with various isocyanantes to yield the product shown as ~~fromula~~ formula V below:



V

28. (canceled)